Inovio Pharmaceu Stock Price, News & Analysis

INOVIO (NASDAQ: INO) has announced a corporate reorganization aimed at cutting operational expenses by around 30% over the next 18 months. The restructuring involves an 18% reduction in full-time employees and an 86% cut in contractors, expected to extend the company's cash runway into Q3 2024. A one-time restructuring charge of approximately $1.6 million is anticipated. The cost-saving measures will allow the company to concentrate on key clinical programs, including its COVID-19 vaccine candidate and HPV initiatives, enhancing its growth prospects in the biotech sector.

INOVIO (NASDAQ: INO) announced the approval of equity grants to Dr. Michael John Sumner, the newly appointed Chief Medical Officer, as part of its 2022 Inducement Plan. The grants included a restricted stock unit (RSU) award of 105,000 shares, vesting over three years, and a stock option to purchase 160,000 shares at an exercise price of $1.73. Both awards are contingent on Dr. Sumner's continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects INOVIO's commitment to attract top talent in biotechnology.

INOVIO (NASDAQ: INO) has appointed Dr. Michael Sumner as its new Chief Medical Officer. With over 25 years of experience in clinical development and regulatory affairs, Dr. Sumner will oversee INOVIO's clinical-stage pipeline, including clinical operations and regulatory affairs. He previously served as CMO of Orexo AB and held roles at Novartis Pharmaceuticals and other major pharmaceutical companies. His expertise in guiding companies through product approvals is expected to bolster INOVIO's efforts in developing DNA medicines aimed at infectious diseases and cancers.

INOVIO (NASDAQ: INO) announced promising results from a Phase 1/2 trial evaluating INO-5401 and INO-9012 in combination with Libtayo^® for newly diagnosed glioblastoma (GBM). The study reported a median overall survival (OS) of 32.5 months for MGMT methylated patients, outperforming historical data. The combination therapy showed a tolerable safety profile and elicited immune responses, with activated T cells identified. Dr. David Reardon will present these findings at ASCO on June 6, 2022, emphasizing the potential of this novel treatment approach for GBM patients.

INOVIO (NASDAQ: INO) announced that President and CEO Jacqueline Shea, along with Jeffrey Skolnik, SVP of Clinical Development for Oncology and HPV Therapeutics, will participate in a fireside chat and individual investor meetings at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 1:00 PM EDT. A webcast of the presentation will be available on the INOVIO Investor Relations Events page. The company focuses on developing DNA medicines for infectious diseases, cancer, and HPV-associated diseases.

INOVIO (NASDAQ: INO) has shifted its focus to a heterologous booster strategy for its COVID-19 vaccine candidate INO-4800, discontinuing the Phase 3 INNOVATE trial. The decision is based on positive T cell immune response data showing a 6.3-fold increase with INO-4800 as a booster. Additionally, the company is revising plans for VGX-3100 after FDA feedback, requiring more trials for HPV treatment. INOVIO reported Q1 2022 revenue of $199,000, down from $371,000, and a net loss of $79.1 million, or $0.36 per share. Jacqueline Shea has been appointed as the new CEO.

INOVIO has appointed Jacqueline Shea, Ph.D., as President and CEO, effective immediately. Dr. Shea, who joined INOVIO in March 2019 as COO, will succeed Dr. J. Joseph Kim, who has resigned from the board. Dr. Shea possesses over 25 years of leadership experience in biotech, including roles at Aeras and Emergent BioSolutions. The board looks forward to her leadership during challenging times and plans to appoint her as a director post the annual stockholders' meeting on May 16, 2022. Dr. Shea aims to advance INOVIO's DNA medicines technology, improving global patient health.

INOVIO (NASDAQ: INO) will release its first quarter 2022 financial results after market close on May 10, 2022. A live conference call will follow at 4:30 p.m. ET to discuss these results and provide a business update. The company continues to focus on DNA medicines for infectious diseases, cancer, and HPV-related conditions, with candidates VGX-3100 and INO-4800 undergoing evaluation in Phase 3 trials. For more information, visit www.inovio.com.

Geneos Therapeutics announced a successful $17 million Series A2 financing led by Flerie Invest, enhancing its clinical trial for advanced hepatocellular carcinoma (HCC). The funding will expand the GT-30 Phase Ib/IIa trial from 24 to 36 patients, utilizing the personalized cancer vaccine GNOS-PV02 combined with a DNA-encoded cytokine and PD-1 checkpoint inhibitor. Dr. Ted Fjällman joins the Board, bringing European investor expertise. The company reported tumor reduction in over half of the initial patients treated and aims to release further efficacy data in 2022.